Vaxart (VXRT) Stock Is Climbing On COVID-19 Vaccine Data

Vaxart VXRT Stock News

Vaxart Inc (NASDAQ: VXRT) is climbing in the market this morning. The gains come after the company announced positive preclinical data surrounding its COVID-19 vaccine under development. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

VXRT Stock Is Climbing On Vaccine Data

In the press release, Vaxart said that it has obtained positive pre-clinical results for its COVID-19 vaccine candidates. Importantly, several of these candidates generated immune responses in all tested animals after a single dose.

In the release, VXRT reminded investors that it initiated a vaccine development program back in January. The vaccine candidates were based on the company’s VAASTTM oral vaccines platform.

Importantly, the preclinical data shows that antibody responses across all vaccinated groups were statistically signifcant. As such, the company plans on pushing one or more of these candidates into clinical testing.

In a statement, Dr. Sean Tucker, CSO at VXRT, had the following to offer:

These early pre-clinical results are in line with those for our oral influenza vaccine which was protective in a clinical Phase 2 efficacy study. Additional data will inform us on which candidate we will move forward into clinical trials. We are particularly interested in vaccine candidates that can generate mucosal immune responses in addition to serum antibody responses. That is a key feature of our oral vaccines and potentially significant for protection against SARS CoV-2, the virus that causes COVID-19.

The above statement was followed up by Wouter Latour, MD, CEO at VXRT. Here’s what he had to offer:

These results are extremely encouraging, and we should be in a position to select a lead development candidate for cGMP manufacturing and clinical testing in the coming weeks. Our oral vaccines have been shown to protect against respiratory infection based on mucosal immunity, the first line of defense for such infections, as recently published in the Lancet Infectious Diseases. This could be important for an effective vaccine that protects the global population from COVID-19. In addition, the Vaxart vaccine would be administered orally using a room temperature-stable tablet, an enormous logistical advantage over injectables in large vaccination campaigns.

Why Investors Are So Excited

At the end of the day, the news released by Vaxart is huge. After all, we all know that the COVID-19 pandemic is a major issue. Of course, if we want to put an end to this pandemic, we’re going to need three key things. Those include, proper testing, vaccines, and a positive treatment.

While there are several companies that are working on vaccines, Vaxart is one of the frontrunners in the race. With today’s news, the company is showing that its coronavirus vaccines are viable and promising candidates.

With strong candidates in the coronavirus vaccine space, VXRT is a stock that should be watched very closely.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.